TABLE 4.
Lopinavir efficacy after 12 months of treatment in pretreated children by age and sexa
| Age (yr) | Characteristic | Girls | Boys |
|---|---|---|---|
| <12 | No. of children | 9 | 12 |
| Age | 8.6 | 6.4 | |
| Baseline VL (log10 no. of copies/ml) | 4.5 | 4.9 | |
| Baseline no. of LPV mutations | 3 | 3 | |
| Lopinavir dose (mg) | 266 | 266 | |
| AUC0-12 (mg · h/liter) | 108 | 116 | |
| VL decrease (log10 copies/ml) | −1.7 | −2.5 | |
| No. of children with VLs <50 copies/ml | 6 | 6 | |
| >12 | No. of children | 6 | 9 |
| Age | 14.8 | 15 | |
| Baseline VL (log10 copies/ml) | 4.9 | 5.2 | |
| Baseline no. of LPV mutations | 3 | 4 | |
| Lopinavir dose (mg) | 399 | 399 | |
| AUC0-12 (mg · h/liter) | 97 | 75 | |
| VL decrease (log10 no. of copies/ml) | −2.5 | −0.5 | |
| No. of children with VLs <50 copies/ml | 4 | 2 |
a
All values provided are median values. LPV, lopinavir; VL, viral load.